WorldPharmaNews
Search ...
Home
Business
Research
Events
Regulatory
GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
www.gsk.com
GlaxoSmithKline RSS Channel
Filters
Display #
5
10
15
20
25
30
50
100
All
Filter
List of articles in category GlaxoSmithKline
Title
Published Date
GSK and Theravance announce completion of the Phase III programme for once-daily LAMA/LABA (UMEC/VI) in COPD
26 August 2012
GlaxoSmithKline reaches agreement to divest majority of Classic Brands in Australia for £172m
15 August 2012
GSK to acquire Human Genome Sciences for US$14.25 per share in cash
16 July 2012
GSK and Theravance announce regulatory submissions for FF/VI
15 July 2012
Innovative public-private collaboration launches to tackle antibiotic research
24 May 2012
GlaxoSmithKline to fully acquire Cellzome for £61 million
15 May 2012
GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
11 May 2012
GlaxoSmithKline and Yale University establish drug discovery collaboration
03 May 2012
GSK confirms offer to acquire Human Genome Sciences for US$13.00 per share in cash
20 April 2012
GSK provides update on corporate responsibility commitments in 2011 report
19 April 2012
Start
Prev
5
6
7
8
9
10
11
12
13
14
Next
End
Business & Industry
GSK completes acquisition of Sierra Oncology
Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron
Research & Development
Researchers discover new leukemia-killing compounds
Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
Biomarkers found that could be drug targets against a deadly form of brain cancer
COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
Novel drug combo activates natural killer cell immunity to destroy cancer cells
Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants
A new technology offers treatment for HIV infection through a single injection
Conferences & Events
New approach to treatment of deadly kidney cancer
SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
SMi's 22nd Annual Pain Therapeutics Conference
SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
SMi's 3rd Annual AI in Drug Discovery Conference
Regulatory Affairs
FDA approves first systemic treatment for alopecia areata
FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
FDA limits use of Janssen COVID-19 vaccine to certain individuals
EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
FDA approves first generic of Symbicort to treat asthma and COPD
You are here:
Home
GlaxoSmithKline
GSK completes acquisition of Sierra Oncology